171856-35-2

Upstream product

• 103-67-3 benzyl-methyl-amine 
• 2900-27-8 (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid 
• 180060-76-8 (S)-[(benzyl-methyl-carbamoyl)-phenyl-methyl]-carbamic acid tert-butyl ester 

Downstream Products

• 481658-94-0 Dirlotapide 
• 889864-23-7 C₃₈H₃₂F₃N₃O₃ 
• 889864-13-5 C₃₈H₃₂F₃N₃O₄ 
• 889863-96-1 C₃₆H₂₉F₃N₄O₃ 
• 889864-04-4 C₃₈H₃₂F₃N₃O₄ 
• 889864-48-6 C₃₆H₃₄F₃N₃O₃ 
• 889864-39-5 C₃₉H₃₃F₃N₄O₄ 
• 889864-30-6 C₃₈H₃₂F₃N₃O₃S 

Relevant academic research and scientific papers

Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents

We have successfully identified a number of novel MTP inhibitors with single digit nanomolar potency. Analogues 10aq and 10dq demonstrated in vivo efficacy in a murine gut retention assay.

Modification of the potent peptide FK888 with unusual aminoacids: Effects on activity on neurokinin receptors

We report on the synthesis and the pharmacological properties of a new series of tachykinin antagonists based on the peptide N2-[(4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-prolyl]-N-m ethyl-N-(phe-nylmethyl)-3-(2-naphthyl)-L-alaninamide (FK888) modified on the (2-naphthyl)-L-alanine and the [(1-methyl-1H-indol-3-yl)carbonyl] moieties. The compounds were tested on guinea pig ileum for NK-1, rat colon for NK-2 and rat portal vein for NK-3 receptors. The two most potent peptides of this series, 1b and 2d, were selective for the NK-2 receptor (pA2 = 7.5 and 7.3, respectively).